FIRST LINE OF TREATMENT OF CHRONIC MYELOID LEUKEMIA IN CHILDREN AND ADOLESCENTS IN THE REPUBLIC OF BELARUS
-
Published:2018-09-16
Issue:3
Volume:15
Page:306-314
-
ISSN:2524-2350
-
Container-title:Proceedings of the National Academy of Sciences of Belarus, Medical series
-
language:
-
Short-container-title:Vescì Nac. akad. navuk Belarusì, Ser. med. navuk
Abstract
Survival was cardinally increased after introducing Imatinib into the first line of therapy of chronic myeloid leukemia (CML) in children. However primary or second resistance was observed in 20–30 % of patients. For the purpose of detection of prognostic factors, a minimal residual disease was monitored in 22 patients at an age of 0–17 years. Furthermore, different variants of BCR/ABL transcript were identified. The results showed that patients with an early major molecular response and a b3a2 variant of the BCR/ABL transcript had significantly better results of treatment. In conclusion, a regular monitoring of a deep molecular response and a further correction of therapy allowed one to increase long-term overall survival in children with CML.
Publisher
Publishing House Belorusskaya Nauka
Reference21 articles.
1. Nikulina O. V., Tsaur G. A., Riger T. O., Yakovleva Yu. A., Demina A. S., Semenikhina E. R., Spil’nik T. V., Savel’ev L. I., Fechina L. G. Diagnostic strategy for detection of typical and atypical BCR-ABL fusion gene transcripts in chronic myeloid leukemia. Klinicheskaya onkogematologiya. Fundamental’nye issledovaniya i klinicheskaya praktika [Clinical Oncohematology. Basic Research and Clinical Practice], 2015, vol. 8, no. 2, pp. 161–168 (in Russian). 2. Falchi L., Kantarjian H. M., Wang X., Verma D., Quintás-Cardama A., O’Brien S., Jabbour E. J., Ravandi-Kashani F., Borthakur G., Garcia-Manero G., Verstovsek S., Burger J. A., Luthra R., Cortes J. E. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. American Journal of Hematology, 2013, vol. 88, no. 12, pp. 1024–1029. https://doi.org/10.1002/ajh.23560 3. Gabert J., Beillard E., van der Velden V. H. J., Bi W., Grimwade D., Pallisgaard N., Barbany G., Cazzaniga G., Cayuela J. M., Cavé H., Pane F., Aerts J. L. E., De Micheli D., Thirion X., Pradel V., González M., Viehmann S., Malec M., Saglio G., van Dongen J. J. M. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe against Cancer Program. Leukemia, 2003, vol. 17, no. 12, pp. 2318–2357. https://doi.org/10.1038/sj.leu.2403135 4. Baccarani M., Deininger M. W., Rosti G., Hochhaus A., Soverini S., Apperley J. F., Cervantes F., Clark R. E., Cortes J. E., Guilhot F., Hjorth-Hansen H., Hughes T. P., Kantarjian H. M., Kim D.-W., Larson R. A., Lipton J. H., Mahon F.-X., Martinelli G., Mayer J., Muller M. C., Niederwieser D., Pane F., Radich J. P., Rousselot P., Saglio G., Saussele S., Schiffer C., Silver R., Simonsson B., Steegmann J.-L., Goldman J. M., Hehlmann R. European Leukemia Net recommendations for the management of chronic myeloid leukemia. Blood, 2013, vol. 122, no. 6, pp. 872–884. https://doi.org/10.1182/blood-2013-05-501569 5. Iacobucci I., Saglio G., Rosti G., Testoni N., Pane F., Amabile M., Poerio A., Soverini S., Bassi S., Cilloni D., Bassan R., Breccia M., Lauria F., Izzo B., Merante S., Frassoni F., Paolini S., Montefusco E., Baccarani M., Martinelli G. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in Imatinib-treated chronic myeloid leukemia patients. Clinical Cancer Research, 2006, vol. 12, no. 10, pp. 3037–3042. https:// doi.org/10.1158/1078-0432.ccr-05-2574
|
|